With the consistent growth of therapeutic antibodies in global market, many efforts have been made to improve the engineering technologies, safety and efficacy of therapeutic antibodies, among which stability is one of the most important functional requirements for the use of antibodies in therapeutic and diagnostic applications.we have particularly developed a sequence-oriented, partially-rational engineering strategy for improving thermal stability of antibody and antibody fragments. Based on our expertise in antibody affinity improvement, we are familiar with the amino acid changes that have been observed in functional antibodies; we identify the minimal potential sites for stability improvement and screening for candidates which will not affect and even increase the binding affinity, through which dramatic stabilization can be achieved and the procedure can be greatly simplified compared with conventional randomization approaches. The scFv fragments with increased thermal stability can retain their binding activities at 65-70°C for over 90 minutes.